Subtype
Colorectal Neoplasm
CI-CAN-00002404Explore in graph →
Non-malignant1,784 active trials21 approved drugs382 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002404Explore in graph →
Clinical trials
8,604 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02579278 | Circulating Tumour DNA (ctDNA) in Patients With Colorectal Cancer and the Relationship to Imaging Features of Extramural Venous Invasion(ctDNA) | recruiting | — | 100 | Imperial College LondonOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT02704520 | Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial(TRIGGER) | recruiting | N/A | 441 | Imperial College LondonOTHER |
| 1 |
| Oct 17, 2024 |
| clinicaltrials |
| NCT03303547 | Concordance of Imaging and Pathology Diagnosis of Extranodal Tumour Deposits(COMET) | recruiting | N/A | 200 | Imperial College LondonOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04547166 | A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) | recruiting | Phase 2 / Phase 3 | 568 | Shanghai Henlius BiotechINDUSTRY | 2 | Oct 17, 2024 | clinicaltrials |
| NCT06275958 | DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer(DOSAGE) | recruiting | Phase 3 | 587 | Leiden University Medical CenterOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06633133 | Virtual Ileostomy Versus Diverting Ileostomy in Patients Undergoing Total Mesorectal Excision | recruiting | N/A | 620 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06643429 | Impact of Environmental Factors and Metabolomics on Colorectal Cancer. | active not recruiting | — | 700 | Dong PengOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06645301 | BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies | not yet recruiting | Early Phase 1 | 15 | BioSyngen Pte LtdINDUSTRY | 0 | Oct 16, 2024 | clinicaltrials |
| NCT04584008 | Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics(VISIONARY) | active not recruiting | N/A | 600 | Peking UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05250648 | Clinical Trial on HIPEC With Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)(GECOP-MMC) | recruiting | Phase 4 | 216 | Hospital Universitario de FuenlabradaOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT05955196 | Test of CD47-SIRPα Inhibitors on the Immune Microenvironment Colon Cancer(MACROSWITCH) | recruiting | — | 115 | Institut Paoli-CalmettesOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06184698 | Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer | recruiting | Phase 2 | 173 | Hebei Medical University Fourth HospitalOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06632886 | AI-Assisted Non-Contrast CT for Multi-Cancer Screening | recruiting | N/A | 1,000,000 | Guo ShiWeiOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06220045 | Comparing PP and PVDF Meshes in Midline Laparotomy Closure for High-risk Colorectal Surgery. Impact on Incisional Hernia and Surgical Wound Infection.(PROFIMESH) | recruiting | N/A | 60 | Institut d'Investigació Biomèdica de Girona Dr. Josep TruetaOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06220058 | Comparing Polypropylene Mesh and "Small Bites" Technique in Emergency Colorectal Surgery's Midline Laparotomy Closure. Study for Incisional Hernia Prevention.(BITEME) | recruiting | N/A | 148 | Fernandez ZamoraOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06629051 | 6-year Follow-up Data After the Berberine Intervention Trial | recruiting | — | 891 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06630962 | Evaluating the Impact of Financial Navigation on Financial Catastrophe and Distress for Cancer Care(COST-FIN) | recruiting | N/A | 200 | Northwestern UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06452745 | Early Diagnosis of Colorectal Cancer Based on a Non-invasive Metabolomics Profile(EarlyCRC) | recruiting | — | 2,000 | Institut Investigacio Sanitaria Pere VirgiliOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT05628038 | The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer(TORCH-R) | recruiting | Phase 2 | 93 | Fudan UniversityOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06619886 | TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor | not yet recruiting | Early Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04117945 | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 22 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06614660 | Metabolism Imaging-genomics for Predicting the Surgical Outcomes of Colorectal Cancer | active not recruiting | — | 800 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06614699 | Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Colorectal Cancer Patients | active not recruiting | — | 8,000 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06614751 | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway | not yet recruiting | Phase 1 | 112 | Danatlas Pharmaceuticals Co., LtdINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06616259 | First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study(CAPCET-III) | not yet recruiting | Phase 3 | 452 | Meng QiuOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06616870 | Study of the Predictive and Prognostic Role of Pharmacogenetic and Radiogenic Variants on the Response to Neoadjuvant Chemoradiation Therapy in Patients With Locally Advanced Rectal Cancer(IGLarc) | not yet recruiting | — | 460 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06613399 | Multi-Technology Integrated Total Mesorectal Excision Versus Conventional Total Mesorectal Excision for the Treatment of Middle and Distal Rectal Cancer. | not yet recruiting | N/A | 324 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Sep 26, 2024 | clinicaltrials |
| NCT06613581 | Patient-led Follow-up from Home After Surgery for Colorectal Carcinoma(PROMISE) | recruiting | N/A | 200 | Erasmus Medical CenterOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06615583 | A Novel Adaptive Anastomotic Technique for Left-sided Colonic Resection(NOVA) | not yet recruiting | N/A | 30 | Istituto Clinico HumanitasOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT05656326 | Follow-up After Surgery for Colorectal Cancer(FUTURE-primary) | active not recruiting | — | 200 | Erasmus Medical CenterOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06259552 | A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors(SPX-303) | recruiting | Phase 1 | 232 | SparX Biotech(Jiangsu) Co., Ltd.OTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT06609551 | ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study(ZJCH-CRCC-1) | recruiting | Phase 3 | 312 | Zhejiang Cancer HospitalOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT06606912 | Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Gastric Cancer Patients | active not recruiting | — | 4,000 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06607614 | A Predictive Model Based on Quantitative Fecal Immunochemical Test Can Stratify the Risk of CRC in an Organized Screening Program(PRIORITIZE) | not yet recruiting | — | 10,000 | Catholic University of the Sacred HeartOTHER | 0 | Sep 23, 2024 | clinicaltrials |
| NCT05961969 | Robotic Top-down Intersphincteric Resection | recruiting | — | 40 | National Taiwan University HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT05964530 | Radical vs Local Excision for Rectal Cancer With Clinically Complete Remission | recruiting | N/A | 180 | National Taiwan University HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT05970133 | Robotic Versus Laparoscopy NOSE for Stage I-III Left-sided Colon Cancer | recruiting | N/A | 300 | National Taiwan University HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06024837 | Performance of Spectral CT-scan in Patients With Metastatic Colorectal Cancer: a Prospective Multicentre Study | recruiting | — | 100 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT02919644 | Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.(COREVAX-1) | recruiting | Phase 2 | 19 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03779009 | Minimally INvasive Colon Cancer Surgery Through IMmunomics and Optical Mapping of the Sentinel Lymph Node.(MINIMAL) | recruiting | N/A | 70 | University Hospital, GhentOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05168839 | Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage(FLUOCOL-1) | recruiting | Phase 3 | 1,010 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06493760 | A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients | recruiting | Phase 2 | 130 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06540261 | The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer | active not recruiting | Phase 1 | 65 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06589388 | ctDNA Monitoring to Predict the Efficacy of TNT for Rectal Cancer | recruiting | — | 100 | Gene SolutionsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06593548 | Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer | not yet recruiting | Phase 2 | 36 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06594692 | Node-Sparing Short-Course Radiation With CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer: A Randomized, Prospective, Multicenter Study(mRCAT-C) | not yet recruiting | Phase 2 | 140 | Sir Run Run Shaw HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06596343 | Evaluating the Benefits of Personalized Traditional Chinese Medicine in Postoperative Treatment for Locally Advanced Colorectal Cancer | not yet recruiting | Phase 2 | 80 | Sir Run Run Shaw HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06599827 | Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC(iMHRT-LARC) | not yet recruiting | Phase 2 | 54 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Oct 17, 2024source: clinicaltrials